Trifarotene
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
Trifarotene: From Acne to zinc, elevated plasma
One-Sentence Summary
Trifarotene is a topical retinoid originally used to treat acne. The TxGNN model (deep learning) predicts it may be effective for zinc, elevated plasma, but this is a model prediction only, with 0 clinical trials and 0 publications supporting it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Acne (acne vulgaris) |
| Predicted New Indication | Zinc, elevated plasma |
| TxGNN Prediction Score | 0.9940 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 1 of 1) |
| Number of DINs | 1 (marketed: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Trifarotene is a selective retinoic acid receptor gamma (RARγ) agonist. The data compiled for this report also list activity at RARα and RARβ. It is applied to the skin as a 0.005% cream. Its high metabolic instability suggests limited systemic exposure. Detailed mechanism-of-action data are not otherwise available in the compiled data.
Its acne use makes mechanistic sense: retinoids normalise keratinocyte differentiation in the hair follicle. No plausible mechanistic link to elevated plasma zinc was identified, and a topical agent with minimal systemic exposure is an unlikely way to change a blood mineral level. The prediction should be regarded as a statistical output of the TxGNN model (deep learning), which may reflect similarities the model learned between related diseases, not biological evidence, and not a mechanistically supported hypothesis.
Other predicted indications were also reviewed. All have only model-prediction support (L5) and no clinical trials or publications. The most biologically coherent one is pyogenic arthritis-pyoderma gangrenosum-acne (PAPA) syndrome (score 0.9932), because it includes severe acne. However, its autoinflammatory drivers (PSTPIP1 mutations, IL-1 pathway) are not targeted by RARγ agonism.
Clinical Trial Evidence
Currently no related clinical trials registered for the predicted indication.
(Trifarotene itself completed Phase 3 trials in acne vulgaris, including the long-term safety study NCT02189629. These relate to the original indication, not the predicted one.)
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02494175 | AKLIEF | Not specified | Not specified |
Safety Considerations
- Drug Interactions: No drug-drug interactions are listed in the compiled data. The three entries returned are pharmacological target bindings, not interactions: trifarotene binds retinoic acid receptors α, β and γ (RARA, RARB, RARG).
- Systemic exposure: Trifarotene is highly metabolically unstable, so systemic exposure is expected to be limited when used topically.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a TxGNN model (deep learning) score alone, which may reflect similarities the model learned between related diseases, not biological evidence. There are no clinical trials, no literature and no plausible mechanistic link. A topical, minimally absorbed agent is poorly suited to altering plasma zinc levels.
To proceed, the following is needed:
- Health Canada package insert warnings and contraindications (a blocking gap for safety screening)
- Detailed mechanism-of-action data
- A biological rationale connecting RAR agonism to zinc homeostasis, plus preclinical or observational evidence
- Consideration of alternative candidates closer to the original indication (e.g., the acne component of PAPA syndrome), which would still require clinical evidence
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.